$18.90
1.29% yesterday
NYSE, Nov 26, 10:05 pm CET
ISIN
US0718131099
Symbol
BAX

Baxter International Stock price

$18.91
-4.26 18.39% 1M
-11.21 37.22% 6M
-10.25 35.15% YTD
-13.96 42.47% 1Y
-36.28 65.74% 3Y
-56.48 74.92% 5Y
-18.97 50.08% 10Y
-2.33 10.95% 20Y
NYSE, Closing price Wed, Nov 26 2025
+0.25 1.34%

New AI Insights on Baxter International Insights AI Insights on Baxter International

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.7b
Enterprise Value
$17.5b
Net debt
$7.8b
Cash
$1.7b
Shares outstanding
514.0m
Valuation (TTM | estimate)
P/E
negative | 7.9
P/S
0.9 | 0.9
EV/Sales
1.6 | 1.6
EV/FCF
71.7
P/B
1.3
Dividends
DPS
$0.52
Yield 1Y | 5Y
2.8% | 1.9%
Growth 1Y | 5Y
-50.0% | -11.5%
Payout 1Y | 3Y
-81.9% | -380.7%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$11.0b | $11.2b
EBITDA
$1.0b | $2.5b
EBIT
$702.0m | $1.6b
Net Income
$-341.0m | $1.2b
Free Cash Flow
$244.0m
Growth (TTM | estimate)
Revenue
-21.2% | 5.7%
EBITDA
-34.4% | 125.8%
EBIT
56.3% | 86.1%
Net Income
-415.7% | 290.4%
Free Cash Flow
-56.3%
Margin (TTM | estimate)
Gross
35.0%
EBITDA
9.1% | 21.9%
EBIT
6.4%
Net
-3.1% | 11.0%
Free Cash Flow
2.2%
Financial Health
Equity Ratio
27.0%
Return on Equity
-9.3%
ROCE
4.1%
ROIC
5.0%
Debt/Equity
1.3
More
EPS
$-0.7
FCF per Share
$0.5
Short interest
8.6%
Employees
38k
Rev per Employee
$280.0k
Show more

Is Baxter International a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Baxter International Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Baxter International forecast:

2x Buy
8%
16x Hold
64%
7x Sell
28%

Analyst Opinions

25 Analysts have issued a Baxter International forecast:

Buy
8%
Hold
64%
Sell
28%

Financial data from Baxter International

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
11,023 11,023
21% 21%
100%
- Direct Costs 7,161 7,161
17% 17%
65%
3,862 3,862
28% 28%
35%
- Selling and Administrative Expenses 2,435 2,435
27% 27%
22%
- Research and Development Expense 569 569
11% 11%
5%
1,001 1,001
34% 34%
9%
- Depreciation and Amortization 299 299
72% 72%
3%
EBIT (Operating Income) EBIT 702 702
56% 56%
6%
Net Profit -341 -341
416% 416%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Baxter International directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Baxter International Stock News

Neutral
PRNewsWire
about 11 hours ago
LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX). IF YOU SUFFERED A LOSS ON YOUR BAXTER INVESTMENTS, CLICK HERE BEFORE DECEMBER 15, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES...
Neutral
PRNewsWire
one day ago
NEW YORK , Nov. 25, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased Baxter common stock during the Class Period you m...
Neutral
PRNewsWire
one day ago
PHILADELPHIA , Nov. 25, 2025 /PRNewswire/ --  Berger Montague advises shareholders of Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) about an investigation into Baxter's Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter's marketing and sale of its Novum Large Volume Pump ("Novum LVP").  Shareholders of ...
More Baxter International News

Company Profile

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Head office United States
CEO D. Shafer
Employees 38,000
Founded 1931
Website www.baxter.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today